Compare Aon PLC (AON) vs DexCom, Inc. (DXCM) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Aon PLC vs DexCom, Inc. — how do they compare? Aon PLC trades at $351.9 (market cap $75.61B), while DexCom, Inc. trades at $89.22 (market cap $33.79B). The key difference: Aon PLC is far larger — about 2.2× DexCom, Inc.'s market cap, and Aon PLC pays a 0.92% dividend while DexCom, Inc. pays none. Which is the better fit depends on your goals.
| AON | DXCM | |
|---|---|---|
Market Cap | $75.61B | $33.79B |
Sector | Financials | Health |
52-Week High | $381.26 | $89.53 |
52-Week Low | $308.22 | $54.84 |
Enterprise Value | $90.22B | $33.24B |
Dividend Yield | 0.92% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AON trades at $356.97, down 0.37% with neutral technical signals. The company shows strong fundamentals with Q2 2026 EPS beating estimates at $3.81 versus $3.80 expected, marking the third consecutive quarterly beat. Revenue growth accelerated to 5% organic in Q2 2026, while margins expanded 70 basis points. Analyst consensus price target stands at $410, representing 15% upside potential from current levels.
AON presents a compelling investment case with consistent earnings outperformance and robust profitability metrics including 44.88% ROE. However, premium valuation multiples and modest organic growth create headwinds. The stock offers 15% upside to consensus targets but requires monitoring of valuation compression risks amid competitive insurance brokerage markets.
DexCom (DXCM) trades at $87.65, up 3.42% today and near its 52-week high, with a bullish technical signal from moving averages and strong fundamental performance. Revenue grew to $4.66B in 2025, with net income reaching $836.30M and a 20.12% net margin. Recent Q2 2026 earnings beat expectations with $0.70 EPS, and the company raised full-year guidance, reflecting robust demand for its continuous glucose monitoring systems.
The outlook remains positive given consistent earnings beats, margin expansion, and analyst consensus favoring a buy rating with a $88.65 price target. Key risks include competitive pressures in medical devices and potential regulatory scrutiny, but growth drivers like G7 adoption and international expansion support upside potential for investors.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Aon PLC
Aon is a leading global provider of insurance and reinsurance brokerage and human resource solutions. Its operations are tilted toward its brokerage operations. Headquartered in London, Aon has about 50,000 employees and operations in 120 countries around the world.
Read more on AON →About DexCom, Inc.
Dexcom designs and commercializes continuous glucose monitoring systems for diabetics. CGM systems serve as an alternative to the traditional blood glucose meter process, and the company is evolving its CGM systems to include the disposable sensor and the durable receiver.
Read more on DXCM →
